Nolibeta (Nebivolol)

Nebivolol works by selectively blocking β1‑adrenergic receptors in the heart, which slows heart rate and reduces contractile force. At the same time it stimulates endothelial nitric‑oxide synthase, increasing nitric‑oxide release that relaxes blood vessels. The dual action lowers arterial pressure while supporting better heart function.

The dose of Nolibeta is individualized by the prescribing clinician based on the patient’s blood pressure, heart‑failure status, age, renal function and other medications. The prescriber determines the appropriate strength and titration schedule; patients should follow the written prescription without alteration.

Safety data for nebivolol during pregnancy and lactation are limited. It should only be used if the potential benefit outweighs the possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives and risks with their healthcare provider.

To request Nolibeta, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with older non‑selective agents such as propranolol or the cardio‑selective metoprolol, nebivolol offers additional nitric‑oxide‑mediated vasodilation, which may improve endothelial function and cause fewer metabolic side effects. However, clinical choice depends on individual patient characteristics, comorbidities and physician experience.

Nolibeta tablets should be stored at room temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.

Nolibeta is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a full glass of water; do not crush or chew unless specifically instructed.

Serious adverse events, although uncommon, include severe bradycardia, heart block and bronchospasm, especially in patients with pre‑existing conduction disorders or reactive airway disease. Prompt medical attention is required if symptoms such as fainting, marked slow heart rate, or breathing difficulty occur.

Nolibeta is contraindicated in patients with severe bradycardia, second‑ or third‑degree atrioventricular block, cardiogenic shock, uncontrolled heart failure, or severe asthma/COPD where β‑blockade could worsen airway obstruction. It should also be avoided in individuals with known hypersensitivity to nebivolol or any tablet excipients.